Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CNR2 | P34972 | 3/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.39 |
| ▸ | LOX | P28300 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | SLC8A1 | P32418 | 1/20 | 0.37 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
| ▸ | SCN1A | P35498 | 1/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.35 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17423137 | 1.00 | ALDH1A1 (0.43) | ALDH1A1CNR2SCN9ALOXNPC1 | |
| SCHEMBL17423077 | 0.89 | ALDH1A1 (0.42) | ALDH1A1SCN9A | |
| SCHEMBL17423109 | 0.89 | ALDH1A1 (0.42) | ALDH1A1SCN9A | |
| SCHEMBL21075446 | 0.82 | SCN9A (0.43) | ALDH1A1SCN9ANPC1POLBSCN1A | |
| SCHEMBL17423020 | 0.81 | SCN9A (0.45) | ALDH1A1SCN9ASCN1ASCN5ASCN2A | |
| SCHEMBL17423116 | 0.77 | SCN9A (0.47) | SCN9ASCN1ASCN5ASCN2A | |
| SCHEMBL17423100 | 0.76 | SCN9A (0.38) | SCN9ASCN1ASCN5ASCN2A | |
| SCHEMBL19064838 | 0.76 | SCN9A (0.38) | CNR2SCN9ASCN1ASCN5ASCN2A | |
| SCHEMBL19064837 | 0.76 | SCN9A (0.38) | CNR2SCN9ASCN1ASCN5ASCN2A | |
| SCHEMBL19064836 | 0.73 | SCN9A (0.37) | SCN9ASCN1ASCN5ASCN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11149002-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2021-10-19 | — | — | US | disclosed |
| US-20210078947-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-03-18 | — | — | US | disclosed |
| EP-3166939-B1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH INC (US) | 2019-06-05 | — | — | EP | disclosed |
| US-20190031607-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-01-31 | — | — | US | disclosed |
| US-10125098-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2018-11-13 | — | — | US | disclosed |
| US-20180265465-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-09-20 | — | — | US | disclosed |
| EP-3166939-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | Genentech, Inc. (US) | 2017-05-17 | — | — | EP | disclosed |
| WO-2016007534-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2016-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11149002-B2 | Therapeutic compounds and methods of use thereof | RDX, C1R, MTX1 | ALDH1A1 1155/4885CNR2 857/4885SCN9A 2337/4885 |
| US-20190031607-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | ALDH1A1 1155/4885CNR2 857/4885SCN9A 2337/4885 |
| US-20180265465-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | ALDH1A1 1155/4885CNR2 857/4885SCN9A 2337/4885 |
| US-10125098-B2 | Therapeutic compounds and methods of use thereof | RDX, C1R, MTX1 | ALDH1A1 1155/4885CNR2 857/4885SCN9A 2337/4885 |
| US-20210078947-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | ALDH1A1 1155/4885CNR2 857/4885SCN9A 2337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.